Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk

Data Sharing Can Accelerate New Discoveries By Avoiding Duplicative Trials, Stimulating New Ideas For Research, And Enabling The Maximal Scientific Knowledge And Benefits To Be Gained From The Efforts Of Clinical Trial Participants And Investigators. At The Same Time, Sharing Clinical Trial Data Presents Risks, Burdens, And Challenges. These Include The Need To Protect The Privacy And Honor The Consent Of Clinical Trial Participants; Safeguard The Legitimate Economic Interests Of Sponsors; And Guard Against Invalid Secondary Analyses, Which Could Undermine Trust In Clinical Trials Or Otherwise Harm Public Health. Sharing Clinical Trial Data Presents Activities And Strategies For The Responsible Sharing Of Clinical Trial Data. With The Goal Of Increasing Scientific Knowledge To Lead To Better Therapies For Patients, This Book Identifies Guiding Principles And Makes Recommendations To Maximize The Benefits And Minimize Risks. This Report Offers Guidance On The Types Of Clinical Trial Data Available At Different Points In The Process, The Points In The Process At Which Each Type Of Data Should Be Shared, Methods For Sharing Data, What Groups Should Have Access To Data, And Future Knowledge And Infrastructure Needs. Responsible Sharing Of Clinical Trial Data Will Allow Other Investigators To Replicate Published Findings And Carry Out Additional Analyses, Strengthen The Evidence Base For Regulatory And Clinical Decisions, And Increase The Scientific Knowledge Gained From Investments By The Funders Of Clinical Trials. The Recommendations Of Sharing Clinical Trial Data Will Be Useful Both Now And Well Into The Future As Improved Sharing Of Data Leads To A Stronger Evidence Base For Treatment. This Book Will Be Of Interest To Stakeholders Across The Spectrum Of Research--from Funders, To Researchers, To Journals, To Physicians, And Ultimately, To Patients. Introduction -- Guiding Principles For Sharing Clinical Trial Data -- The Roles And Responsibilities Of Stakeholders In The Sharing Of Clinical Trial Data -- The Clinical Trial Life Cycle And When To Share Data -- Access To Clinical Trial Data: Governance -- The Future Of Data Sharing In A Changing Landscape -- Study Approach -- Concepts And Methods For De-identifying Clinical Trial Data -- Legal Discussion Of Risks To Industry Sponsors -- Clinical Trial Data Sharing Policies: Top 12 Pharmaceutical Companies Ranked By 2013 Market Capitalization. Committee On Strategies For Responsible Sharing Of Clinical Trial Data, Board On Health Sciences Policy, Institute Of Medicine. Title From Pdf Title Page. Includes Bibliographical References. This Study Was Supported By Contracts Between The National Academy Of Sciences And The U.s. National Institutes Of Health (hhsn263201200074i), U.s. Food And Drug Administration, Abbvie Inc., Amgen Inc., Astrazeneca Pharmaceuticals, Bayer, Biogen Idec, Bristol-myers Squibb, Burroughs Wellcome Fund, Doris Duke Charitable Foundation, Eli Lilly And Company, Emd Serono, Genentech, Glaxosmithkline, Johnson & Johnson, Medical Research Council (uk), Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., Sanofi-aventis, Takeda, And The Wellcome Trust. Any Opinions, Findings, Conclusions, Or Recommendations Expressed In This Publication Are Those Of The Author(s) And Do Not Necessarily Reflect The Views Of The Organizations Or Agencies That Provided Support For The Project.